explore -WSS

explore

author：comprehensive 2025-09-30 16:26:51 - browse：91

A sign of Gilead Sciences sits in front of its headquarter and next to a pedestrian crossing sign — health coverage from STAT — Justin Sullivan/Getty Images

The assault on the development of new lifesaving therapies continues apace. Recently, the First Appellate Division of California Appeals held that companies not only have to defend products they have developed and marketed, but also those they have not.

In 2001, Gilead secured FDA approval of tenofovir disoproxil fumarate (TDF), one of first medicines to treat HIV — a product still on the market, despite the potential side effect of causing skeletal and kidney damage. In the years that followed, the company invested in research leading to additional TDF-based regimens critical to the fight against HIV. It had also done preliminary work on a similar but different drug — tenofovir alafenamide fumarate (TAF) — for which it had early, although not definitive, evidence for safety and efficacy.

Ultimately, this medicine was shown to have a better side effect profile than TDF. Starting in 2018, plaintiffs began suing Gilead for negligently failing to develop TAF earlier, on the theory that it wanted to protect the profits from TDF. Now, the California court has agreed to let the suit proceed.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： State of the Union pitch: Bigger Medicare drug price negotiations

focus

WSS

Listen: More tumult at BIO & coercive care for sickle cell patients

Harvard's David Sinclair gets blowback over aging

$1 billion proposal to grow Boston, Massachusetts biotech

Investigation reveals sickle cell patients pressured into sterilizations

ASCO eve: Let’s set the table for this year's meeting

Digital health: a case of mistaken identity

Wikipedia

explore

hotspot

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Immune cells and nerve overgrowth may explain recurring UTI pain

Medicare details structure of new drug price negotiation program

H5N1 bird flu outbreak: Second human case reported, in Michigan

Hepatitis C has a cure — but many Americans still lack access to it

Immune cells and nerve overgrowth may explain recurring UTI pain

Hepatitis C has a cure — but many Americans still lack access to it

As a primary care physician, here's how I hope to partner with AI

Hollywood unions extend contract negotiations for actors

As a primary care physician, here's how I hope to partner with AI

focus

Lack of health data on LGBTQ+ people has serious consequences

Pregnant women don't need prenatal multivitamins, study concludes

ASCO eve: Let’s set the table for this year's meeting

Harvard's David Sinclair gets blowback over aging

Immune cells and nerve overgrowth may explain recurring UTI pain

Medicare drug price negotiation continues, as pharma counteroffers

focus

focus

hotspot

focus